Triphasic oral contraceptive

Details Triphasic oral contraceptive Triphasic oral contraceptive

1985-06-11

1986-12-09

Roberts, Elbert L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514177, 514182, A61K 3156, A01N 4500

Patent

active

046280510

ABSTRACT:
A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen.

REFERENCES:
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale

Affiliated with

Also associated with

Rating

Triphasic oral contraceptive does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triphasic oral contraceptive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triphasic oral contraceptive will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1385534